T
Terry L. Ng
Researcher at University of Ottawa
Publications - 50
Citations - 1428
Terry L. Ng is an academic researcher from University of Ottawa. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 11, co-authored 34 publications receiving 756 citations. Previous affiliations of Terry L. Ng include Ottawa Hospital Research Institute & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.
Journal ArticleDOI
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Yan Wang,Tao Jiang,Z. Qin,J. Jiang,Q. Wang,Shuo Yang,Christopher J. Rivard,Guanghui Gao,Terry L. Ng,Megan M. Tu,Hui Yu,Hongbin Ji,Caicun Zhou,Shengxiang Ren,Shengxiang Ren,Jun Zhang,Paul A. Bunn,Robert C. Doebele,D.R. Camidge,Fred R. Hirsch +19 more
TL;DR: Pyrotinib showed activity against NSCLC with HER2 exon 20 mutations in both patient-derived organoids and a PDX model and showed promising efficacy in the clinical trial.
Journal ArticleDOI
Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
TL;DR: Despite extensive use of bone-targeted agents for breast cancer patients with bone metastases treated in the non-trial setting, the incidence of SREs remains high and use of opioids and hospitalizations secondary toBone metastases remain common.
Journal ArticleDOI
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
Megan M. Tu,Francis Y. Lee,Robert T. Jones,Abigail K. Kimball,Elizabeth Saravia,Robert F. Graziano,Brianne M. Coleman,Krista Menard,Jun Yan,Erin Michaud,Han Chang,Hany A. Abdel-Hafiz,Andrii I. Rozhok,Jason E. Duex,Neeraj Agarwal,Ana Chauca-Diaz,Linda K. Johnson,Terry L. Ng,John C. Cambier,Eric T. Clambey,James C. Costello,Alan J. Korman,Dan Theodorescu +22 more
TL;DR: This work shows that DDR2 depletion increases sensitivity to anti–PD-1 treatment compared to monotherapy, and provides strong scientific rationale for targeting DDR2 in combination with PD-1 inhibitors.
Journal ArticleDOI
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non–small cell lung cancer
Terry L. Ng,Yiwei Liu,Anastasios Dimou,Tejas Patil,Dara L. Aisner,Zhengwei Dong,Tao Jiang,Chunxia Su,Chunyan Wu,Shengxiang Ren,Caicun Zhou,D. Ross Camidge +11 more
TL;DR: This multicenter, retrospective study explored the value of oncogene driver subtype, programmed death‐1 ligand (PD‐L1) status, and smoking status for predicting which patients with oncogen‐driven non–small cell lung cancer (NSCLC) would benefit from treatment with programmed death-1/PD‐1)/PD‐ L1 inhibitors.